CTOs on the Move


 
Amway is the world`s No. 1 direct selling business, according to the Direct Selling News Global 100. Established in 1959, with sales of $8.6 billion, Amway operates in more than 100 countries and territories. We manufacture and distribute 450+ consumer products that support health and well-being. More than 19,000 employees worldwide support millions of Amway Business Owners who sell Amway products. Headquartered in Ada, Michigan, Amway is a center of health, skincare and home product innovation and top-selling, global brands. In addition, we are a company committed to providing employees with challenging career opportunities, a comprehensive total rewards package, profit ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.amway.com
  • 7575 Fulton Street East
    Ada, MI USA 49355
  • Phone: 616.787.1000

Executives

Name Title Contact Details
Ali Syed
VP Information Security and Risk (CISO) Profile

Similar Companies

Glendale Adventist Medical Center

The purpose of the Healthcare Foundation is to support the work and mission of Glendale Adventist Medical Center through philanthropy. Foundation responsibilities include the receipt and disbursement of all gifts to the Medical Center, as well as the

Sterling Life Sciences

Sterling Life Sciences is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zeltiq Aesthetics Inc

Zeltiq Aesthetics Inc is a Pleasanton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Five Rivers Medical Center

Five Rivers Medical Center is a Pocahontas, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.